Cargando…

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

PURPOSE: The receptor tyrosine kinase rearranged during transfection (RET) can be oncogenically activated by gene fusions or point mutations. Multikinase inhibitors such as cabozantinib, lenvatinib and vandetanib have demonstrated activity in RET-dependent malignancies, and selective RET inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hegde, Aparna, Andreev-Drakhlin, Alexander Y, Roszik, Jason, Huang, Le, Liu, Shuang, Hess, Kenneth, Cabanillas, Maria, Hu, Mimi I, Busaidy, Naifa L, Sherman, Steven I, Dadu, Ramona, Grubbs, Elizabeth G, Ali, Siraj M, Lee, Jessica, Elamin, Yasir Y, Simon, George R, Blumenschein, Jr, George R, Papadimitrakopoulou, Vassiliki A, Hong, David, Meric-Bernstam, Funda, Heymach, John, Subbiah, Vivek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590373/ https://www.ncbi.nlm.nih.gov/pubmed/33097651 http://dx.doi.org/10.1136/esmoopen-2020-000799

Ejemplares similares

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
por: Adashek, Jacob J., et al.
Publicado: (2021)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Neoadjuvant selpercatinib for advanced medullary thyroid cancer
por: Jozaghi, Yelda, et al.
Publicado: (2020)

Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
por: Hamidi, Sarah, et al.
Publicado: (2023)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
por: Busaidy, Naifa Lamki, et al.
Publicado: (2012)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

MON-554 Brain Metastases in Thyroid Cancer: Molecular Profile and Institutional Experience of a Single Tertiary Referral Center in the Era of Kinase Inhibitor Therapy
por: Agosto Salgado, Sarimar, et al.
Publicado: (2019)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Antibody-drug conjugates in lung cancer: dawn of a new era?
por: Coleman, Niamh, et al.
Publicado: (2023)

MON-491 TRK-Fusion Thyroid Cancer: A Clinical Overview in a Large Population at a Single Cancer Center
por: Fazeli, Sasan, et al.
Publicado: (2020)

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
por: Subbiah, Vivek, et al.
Publicado: (2014)

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
por: Wang, Yudong, et al.
Publicado: (2018)

MON-LB015 Sporadic MTC in Children: Characterization of a Rare Disease
por: Gammons, Sarah, et al.
Publicado: (2020)

Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns
por: Nguyen, Ha, et al.
Publicado: (2021)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Recent advances and emerging therapies in anaplastic thyroid carcinoma
por: Cabanillas, Maria E., et al.
Publicado: (2018)

Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer
por: Thein, Kyaw Z., et al.
Publicado: (2022)

PSAT385 Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer
por: Vodopivec, Danica M, et al.
Publicado: (2022)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

MON-LB097 The Genomic Landscape of Preoperative FNAs Positive for the Afirma GSC Medullary Thyroid Cancer Classifier
por: Waguespack, Steven, et al.
Publicado: (2019)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
por: Pairawan, Seyed, et al.
Publicado: (2022)

Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation
por: Cuglievan, Branko, et al.
Publicado: (2018)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient
por: Bagheri-Yarmand, Rozita, et al.
Publicado: (2021)

Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design
por: Dimou, Anastasios, et al.
Publicado: (2014)

Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
por: Hahn, Andrew W, et al.
Publicado: (2020)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF(V600E) Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study
por: Zhao, Xiao, et al.
Publicado: (2023)

Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma
por: Wang, Jennifer Rui, et al.
Publicado: (2022)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_q2tf0ma1b4ijq3ik7sfjpd5g1d